Since the lead curaxin CBL0137, the first indirect FACT inhibitor, is currently in clinical trials, we addressed the important question concerning the consequences of FACT inactivation in “high” and “low” FACT expressing tumor cells. The gene discussed is SUPT16H; the disease is neoplasm.